Article
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
PloS one - 16 Jun 2010
Dusa Alexandra, Mouton Céline, Pecquet Christian, Herman Murielle, Constantinescu Stefan N
Abstract excerpt
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Thrombocythemia and Primary Myelofibrosis patients renders the kinase constitutively active. In the absence of a three-dimensional structure for the full-length protein, the mechanism of activation of JAK2 V617F has remained elusive. In this study, we used functional mutagenesis to investigate the involvement of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.